Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAFV600E Mutation and BRAF Pseudogene

Jiunn-Diann Lin, Shuai Shuai Fu, Jui Yu Chen, Chen Hsen Lee, Wing Keung Chau, Chao-Wen Cheng, Yuan-Hung Wang, Yuh-Feng Lin, Wen Fang Fang, Kam Tsun Tang

研究成果: 雜誌貢獻文章

6 引文 (Scopus)

摘要

Background: The association of BRAFV600E with the clinical manifestations of papillary thyroid carcinoma (PTC) remains controversial. Recent studies have shown that the BRAF pseudogene can activate the MAPK pathway and induce tumorigenesis. This study investigated the association of BRAFV600E, the BRAF pseudogene, and their mRNA levels with clinical features and thyroid-specific gene expression in conventional PTCs. Materials and Methods: A total of 78 specimens were collected from patients with conventional PTCs. RNA was isolated, and quantitative polymerase chain reaction was used to measure the mRNA levels of BRAF, the BRAF pseudogene, and thyroid-specific and tumor-related genes. Immunohistochemical (IHC) staining of BRAF, ERK, sodium-iodide symporter (NIS), thyrotropin receptor, glucose transporter 1, and Ki67 was also performed. Results: BRAFV600E and the BRAF pseudogene were detected in 73.0% (57/78) and 91.7% (44/48), respectively, of the conventional PTCs. The presence of BRAFV600E was not associated with the multiple clinical features assessed or the recurrence rate during 76.9 ± 47.2 months of follow-up. Neither was it associated with IHC staining or tumor-related/thyroid-specific gene expression, except for decreased NIS gene expression. The BRAF pseudogene was not associated with clinical characteristics or thyroid-specific gene expression, except for decreased decoy receptor 3 (DCR3) expression. High BRAF mRNA levels were associated with bilateral and multifocal lesions, and BRAF-pseudogene mRNA levels were positively correlated with BRAF mRNA levels (r = 0.415, p = 0.009). Conclusion: These results do not support the use of the BRAFV600E mutation as a prognostic marker of conventional PTC. However, the association of high BRAF mRNA levels with more advanced clinical features suggests that BRAF mRNA levels might be a more useful clinical marker of PTCs, independent of the BRAFV600E mutation status. The correlation between BRAF-pseudogene mRNA levels and BRAF mRNA levels in PTCs is in agreement with the hypothesis that the BRAF pseudogene regulates BRAF expression during tumorigenesis by acting as competitive noncoding RNA. However, additional studies with larger sample sizes are required to confirm these findings.
原文英語
頁(從 - 到)691-704
頁數14
期刊Thyroid
26
發行號5
DOIs
出版狀態已發佈 - 五月 1 2016

指紋

Pseudogenes
Factor IX
Gene Expression
Messenger RNA
Mutation
Thyroid Gland
Carcinogenesis
Staining and Labeling
Papillary Thyroid cancer
Thyrotropin Receptors
Untranslated RNA
Facilitative Glucose Transport Proteins
Sample Size
Neoplasms
Biomarkers
RNA
Recurrence
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

引用此文

Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAFV600E Mutation and BRAF Pseudogene. / Lin, Jiunn-Diann; Fu, Shuai Shuai; Chen, Jui Yu; Lee, Chen Hsen; Chau, Wing Keung; Cheng, Chao-Wen; Wang, Yuan-Hung; Lin, Yuh-Feng; Fang, Wen Fang; Tang, Kam Tsun.

於: Thyroid, 卷 26, 編號 5, 01.05.2016, p. 691-704.

研究成果: 雜誌貢獻文章

Lin, Jiunn-Diann ; Fu, Shuai Shuai ; Chen, Jui Yu ; Lee, Chen Hsen ; Chau, Wing Keung ; Cheng, Chao-Wen ; Wang, Yuan-Hung ; Lin, Yuh-Feng ; Fang, Wen Fang ; Tang, Kam Tsun. / Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAFV600E Mutation and BRAF Pseudogene. 於: Thyroid. 2016 ; 卷 26, 編號 5. 頁 691-704.
@article{47051f6442e44ef680862db781cf7c9b,
title = "Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAFV600E Mutation and BRAF Pseudogene",
abstract = "Background: The association of BRAFV600E with the clinical manifestations of papillary thyroid carcinoma (PTC) remains controversial. Recent studies have shown that the BRAF pseudogene can activate the MAPK pathway and induce tumorigenesis. This study investigated the association of BRAFV600E, the BRAF pseudogene, and their mRNA levels with clinical features and thyroid-specific gene expression in conventional PTCs. Materials and Methods: A total of 78 specimens were collected from patients with conventional PTCs. RNA was isolated, and quantitative polymerase chain reaction was used to measure the mRNA levels of BRAF, the BRAF pseudogene, and thyroid-specific and tumor-related genes. Immunohistochemical (IHC) staining of BRAF, ERK, sodium-iodide symporter (NIS), thyrotropin receptor, glucose transporter 1, and Ki67 was also performed. Results: BRAFV600E and the BRAF pseudogene were detected in 73.0{\%} (57/78) and 91.7{\%} (44/48), respectively, of the conventional PTCs. The presence of BRAFV600E was not associated with the multiple clinical features assessed or the recurrence rate during 76.9 ± 47.2 months of follow-up. Neither was it associated with IHC staining or tumor-related/thyroid-specific gene expression, except for decreased NIS gene expression. The BRAF pseudogene was not associated with clinical characteristics or thyroid-specific gene expression, except for decreased decoy receptor 3 (DCR3) expression. High BRAF mRNA levels were associated with bilateral and multifocal lesions, and BRAF-pseudogene mRNA levels were positively correlated with BRAF mRNA levels (r = 0.415, p = 0.009). Conclusion: These results do not support the use of the BRAFV600E mutation as a prognostic marker of conventional PTC. However, the association of high BRAF mRNA levels with more advanced clinical features suggests that BRAF mRNA levels might be a more useful clinical marker of PTCs, independent of the BRAFV600E mutation status. The correlation between BRAF-pseudogene mRNA levels and BRAF mRNA levels in PTCs is in agreement with the hypothesis that the BRAF pseudogene regulates BRAF expression during tumorigenesis by acting as competitive noncoding RNA. However, additional studies with larger sample sizes are required to confirm these findings.",
author = "Jiunn-Diann Lin and Fu, {Shuai Shuai} and Chen, {Jui Yu} and Lee, {Chen Hsen} and Chau, {Wing Keung} and Chao-Wen Cheng and Yuan-Hung Wang and Yuh-Feng Lin and Fang, {Wen Fang} and Tang, {Kam Tsun}",
year = "2016",
month = "5",
day = "1",
doi = "10.1089/thy.2015.0044",
language = "English",
volume = "26",
pages = "691--704",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAFV600E Mutation and BRAF Pseudogene

AU - Lin, Jiunn-Diann

AU - Fu, Shuai Shuai

AU - Chen, Jui Yu

AU - Lee, Chen Hsen

AU - Chau, Wing Keung

AU - Cheng, Chao-Wen

AU - Wang, Yuan-Hung

AU - Lin, Yuh-Feng

AU - Fang, Wen Fang

AU - Tang, Kam Tsun

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background: The association of BRAFV600E with the clinical manifestations of papillary thyroid carcinoma (PTC) remains controversial. Recent studies have shown that the BRAF pseudogene can activate the MAPK pathway and induce tumorigenesis. This study investigated the association of BRAFV600E, the BRAF pseudogene, and their mRNA levels with clinical features and thyroid-specific gene expression in conventional PTCs. Materials and Methods: A total of 78 specimens were collected from patients with conventional PTCs. RNA was isolated, and quantitative polymerase chain reaction was used to measure the mRNA levels of BRAF, the BRAF pseudogene, and thyroid-specific and tumor-related genes. Immunohistochemical (IHC) staining of BRAF, ERK, sodium-iodide symporter (NIS), thyrotropin receptor, glucose transporter 1, and Ki67 was also performed. Results: BRAFV600E and the BRAF pseudogene were detected in 73.0% (57/78) and 91.7% (44/48), respectively, of the conventional PTCs. The presence of BRAFV600E was not associated with the multiple clinical features assessed or the recurrence rate during 76.9 ± 47.2 months of follow-up. Neither was it associated with IHC staining or tumor-related/thyroid-specific gene expression, except for decreased NIS gene expression. The BRAF pseudogene was not associated with clinical characteristics or thyroid-specific gene expression, except for decreased decoy receptor 3 (DCR3) expression. High BRAF mRNA levels were associated with bilateral and multifocal lesions, and BRAF-pseudogene mRNA levels were positively correlated with BRAF mRNA levels (r = 0.415, p = 0.009). Conclusion: These results do not support the use of the BRAFV600E mutation as a prognostic marker of conventional PTC. However, the association of high BRAF mRNA levels with more advanced clinical features suggests that BRAF mRNA levels might be a more useful clinical marker of PTCs, independent of the BRAFV600E mutation status. The correlation between BRAF-pseudogene mRNA levels and BRAF mRNA levels in PTCs is in agreement with the hypothesis that the BRAF pseudogene regulates BRAF expression during tumorigenesis by acting as competitive noncoding RNA. However, additional studies with larger sample sizes are required to confirm these findings.

AB - Background: The association of BRAFV600E with the clinical manifestations of papillary thyroid carcinoma (PTC) remains controversial. Recent studies have shown that the BRAF pseudogene can activate the MAPK pathway and induce tumorigenesis. This study investigated the association of BRAFV600E, the BRAF pseudogene, and their mRNA levels with clinical features and thyroid-specific gene expression in conventional PTCs. Materials and Methods: A total of 78 specimens were collected from patients with conventional PTCs. RNA was isolated, and quantitative polymerase chain reaction was used to measure the mRNA levels of BRAF, the BRAF pseudogene, and thyroid-specific and tumor-related genes. Immunohistochemical (IHC) staining of BRAF, ERK, sodium-iodide symporter (NIS), thyrotropin receptor, glucose transporter 1, and Ki67 was also performed. Results: BRAFV600E and the BRAF pseudogene were detected in 73.0% (57/78) and 91.7% (44/48), respectively, of the conventional PTCs. The presence of BRAFV600E was not associated with the multiple clinical features assessed or the recurrence rate during 76.9 ± 47.2 months of follow-up. Neither was it associated with IHC staining or tumor-related/thyroid-specific gene expression, except for decreased NIS gene expression. The BRAF pseudogene was not associated with clinical characteristics or thyroid-specific gene expression, except for decreased decoy receptor 3 (DCR3) expression. High BRAF mRNA levels were associated with bilateral and multifocal lesions, and BRAF-pseudogene mRNA levels were positively correlated with BRAF mRNA levels (r = 0.415, p = 0.009). Conclusion: These results do not support the use of the BRAFV600E mutation as a prognostic marker of conventional PTC. However, the association of high BRAF mRNA levels with more advanced clinical features suggests that BRAF mRNA levels might be a more useful clinical marker of PTCs, independent of the BRAFV600E mutation status. The correlation between BRAF-pseudogene mRNA levels and BRAF mRNA levels in PTCs is in agreement with the hypothesis that the BRAF pseudogene regulates BRAF expression during tumorigenesis by acting as competitive noncoding RNA. However, additional studies with larger sample sizes are required to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=84968754955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968754955&partnerID=8YFLogxK

U2 - 10.1089/thy.2015.0044

DO - 10.1089/thy.2015.0044

M3 - Article

C2 - 26914762

AN - SCOPUS:84968754955

VL - 26

SP - 691

EP - 704

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 5

ER -